AVALYN PHARMA: 2026 Earnings, Market Cap and Growth Outlook
AVALYN PHARMA INC’s June 2026 snapshot: a $1.11B Nasdaq‑listed biotech with a negative P/E yet promising growth, steady stock range, and R&D‑driven upside.
3 minutes to read
AVALYN PHARMA INC